Conclusions:
Prior CABG patients represent a high risk cohort for death and recurrent cardiovascular events but have lower risk for major bleeding. A reduction in ischemic events without increase in major bleeding occurred with ticagrelor vs. clopidogrel in prior CABG patients, similar to the results in non-prior CABG patients.
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Background: There is still uncertainty regarding the optimal dual antiplatelet therapy (DAPT) duration after percutaneous coronary interventions (PCI). We evaluate benefits and risks of extending DAPT after PCI in the drug-eluting stent era. Methods: We searched electronic databases (Medline, EMBASE, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, chapters in books and proceedings of advisory panels for the US Food and Drug Administration, for randomized controlled trials investigating the clinical impact of extending DAPT duration in patients undergoing PCI. The primary endpoint was all-cause death. The secondary endpoints were myocardial infarction (MI), stent thrombosis (ST), cerebrovascular accidents (CVA) Background: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor significantly reduced the risk of thrombotic events compared to clopidogrel in patients with acute coronary syndromes (ACS). We aimed to investigate whether clinical presentation (STEMI vs. NSTE-ACS) has any interaction with platelet inhibition between ticagrelor and clopidogrel. Methods: In a non-prespecified, single-center, pharmacodynamic analysis of the PLATO randomized, blinded, placebo-controlled trial, platelet inhibition was compared in patients randomized to clopidogrel (nϭ55) or ticagrelor (nϭ53) at 24-48 hours of receiving loading doses (LD) and during the maintenance period (Ͼ7 days) of treatment. Maximal platelet aggregation (MPA) was measured with light transmission aggregometry using ADP 5 M. P values for interaction between STEMI and NSTE-ACS were calculated regarding mean MPA and for the odds of high platelet reactivity (HPR, defined as MPAϾ46% 
E-ZES) and the Cypher sirolimus-eluting stent (C-SES).
Methods: PROTECT is a prospective, multicenter, randomized trial conducted at 196 sites in 36 countries worldwide in all continents. Patients with up to 4 coronary lesions amenable for stenting were randomized to receive E-ZES or C-SES. The primary endpoint is the 3 year rate of ARC-defined definite and probable ST. DAPT with clopidogrel and aspirin were prescribed at least for 3 months and at physician discretion for 12 months or longer. Planned and actual duration of DAPT, utilization of aspirin (ASA) and clopidogrel by region, and aspirin dose (Ͻ100mg, 100-300 mg, Ͼ300mg) were collected. Multivariate regression analysis will be used to identify predictors for DAPT duration of Ն12 months, DAPT compliance, and the relationship of these factors with the outcomes of ST, myocardial infarction and cardiac death. Results: PROTECT enrolled 8,800 patients; mean age 62.2Ϯ10.6 years and 76.3% were male. Overall, 44.7% of patients presented with acute coronary syndromes, 27.2% had diabetes mellitus, 20.5% prior MI, and 12.5% prior PCI. Almost all were de novo lesions (98.2%), 46.6% in the left anterior descending artery and 54.8% were B2/C lesions. Details of DAPT usage (planned and actual duration, ASA dosage) by region, and according to patient characteristics will be available for presentation. Conclusions: Analysis of the variation in duration of DAPT across regions and according to patient characteristics in a real world setting will further our understanding of the impact of DAPT on stent specific and global cardiovascular outcomes. Georgtown University, Washington, DC Background: Platelet activation plays a critical role in the pathogenesis of acute myocardial infarction (AMI). This study aimed to determine whether the results of platelet function assays used to measure response to clopidogrel therapy are similar among patients with stable CAD and those with AMI undergoing percutaneous coronary intervention (PCI) both at the index admission and at 30 days' post admission. Methods: Sixty patients were prospectively enrolled into either an elective PCI cohort or an AMI cohort. Patients presenting with an AMI were approached within 24 hours of presentation and following PCI for participation. Patients underwent platelet function testing post-PCI and again at 30 days (Ϯ 2 weeks) follow up. Tests included vasodilator stimulated phosphoprotein phosphorylation (VASP) and VerifyNow P2Y12. Results: The average age of the population was 64.5 Ϯ 11.2 years with no difference between the elective and AMI groups. Baseline characteristics were similar, with an overall rate of diabetes of 26.7%, hypertension 78.3%, current smokers 15.0%, prior CAD 35.0%, renal insufficiency 6.7% and the average BMI was 31 Ϯ 7. The AMI group had higher PRU, percent inhibition, and PRI at the time of PCI as compared to the elective PCI group. This difference was not sustained at 30 days. The PRU significantly decreased at 30 days compared to the PCI procedure for the AMI group. Similarly, the percent inhibition and PRI decreased, but did not achieve statistical significance. (Table) . Conclusions: Platelet reactivity is higher at the time of primary PCI (vs. elective PCI) with AMI presentation. These data support the notion that the platelets become hypersensitive at the time of AMI and are passivated over time given antiplatelet therapy. The on-treatment platelet reactivity should be assessed for patients presenting with AMI to appropriately tailor the antiplatelet regime. 
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